Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 84 results for hepatitis b

  1. Child maltreatment: when to suspect maltreatment in under 18s (CG89)

    This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help health professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.

    Clinical guideline
    Last updated
    9 October 2017
    View recommendations

    Sections for CG89

  2. How can case-finding for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of hepatitis B and hepatitis C infection are identified and tested?

    for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of hepatitis...

    Research recommendation
    Published
    9 June 2015

  3. Drug misuse in over 16s: psychosocial interventions (CG51)

    This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

    Clinical guideline
    Published
    25 July 2007
    View recommendations

    Sections for CG51

  4. Long-term safety of tenofovir disoproxil in chronic hepatitis B:- Further research should be undertaken to determine the long-term safety of tenofovir disoproxil, including the risk of clinically significant hypophosphataemia and related bone toxicity, in people with chronic hepatitis B. The cost effectiveness of routine monitoring for phosphate loss and bone disease in people with chronic hepatitis B who are receiving tenofovir disoproxil treatment needs further evaluation.

    Question Long-term safety of tenofovir disoproxil in chronic hepatitis B:- Further research should be undertaken to determine the...

    Research recommendation
    Published
    9 June 2015

  5. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)

    Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.

    Medical technologies guidance
    Last updated
    17 January 2020
    View recommendations

    Sections for MTG27

  6. Stopping antiviral treatment in HBeAg-negative disease:- Further research should be undertaken to evaluate the clinical and cost effectiveness of hepatitis B surface antigen (HBsAg) quantitative assays in determining treatment duration in hepatitis B e antigen- (HBeAg) negative disease.

    and cost effectiveness of hepatitis B surface antigen (HBsAg) quantitative assays in determining treatment duration in hepatitis...

    Research recommendation
    Published
    9 June 2015

  7. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

    Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA193

  8. What are the most effective ways of involving people from groups at increased risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective are peer mentor programmes at increasing the number of people at increased risk who are tested and treated for hepatitis B and C?

    in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective are...

    Research recommendation
    Published
    9 June 2015

  9. Physical health of people in prisons (QS156)

    This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 September 2017
    View quality statements

    Sections for QS156

  10. What cost-effective interventions ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison?

    ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    9 June 2015

  11. How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Question How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come...

    Research recommendation
    Published
    9 June 2015

  12. How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Question How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?...

    Research recommendation
    Published
    9 June 2015

  13. What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment?

    Question What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing...

    Research recommendation
    Published
    9 June 2015

  14. What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and secondary care?

    Question What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and...

    Research recommendation
    Published
    9 June 2015

  15. Mortality: liver disease (IND282)

    This indicator covers under 75 mortality from liver disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    30 September 2023